Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 70.1% in June

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totaling 8,286 shares, a decline of 70.1% from the May 31st total of 27,683 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 150,990 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Get Our Latest Analysis on Lonza Group

Lonza Group Stock Performance

OTCMKTS LZAGY traded up $0.91 during trading hours on Monday, hitting $66.85. 14,745 shares of the company traded hands, compared to its average volume of 85,100. The business’s 50-day moving average is $62.75 and its 200-day moving average is $65.17. Lonza Group has a twelve month low of $58.53 and a twelve month high of $73.85. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.24.

Lonza Group Company Profile

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

Featured Articles

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.